Loading…
bioAffinity Technologies, Inc. is projected to decline to $0.7072 by 2027, a -8% move from its current price of $0.7666. BIAF is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.7218 | $0.7661 | $0.8131 | -0.06% |
| Jul 14 | $0.7038 | $0.7656 | $0.8329 | -0.13% |
| Jul 15 | $0.6902 | $0.7651 | $0.8482 | -0.19% |
| Jul 16 | $0.6788 | $0.7646 | $0.8613 | -0.26% |
| Jul 17 | $0.6689 | $0.7641 | $0.8729 | -0.32% |
| Jul 18 | $0.66 | $0.7637 | $0.8835 | -0.38% |
| Jul 19 | $0.652 | $0.7632 | $0.8933 | -0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.652 | $0.7632 | $0.8933 | -0.45% |
| Week 2 | $0.6081 | $0.7598 | $0.9493 | -0.89% |
| Week 3 | $0.5758 | $0.7564 | $0.9936 | -1.34% |
| Week 4 | $0.5495 | $0.753 | $1.03 | -1.78% |
| Week 5 | $0.5271 | $0.7496 | $1.07 | -2.22% |
| Week 6 | $0.5074 | $0.7463 | $1.10 | -2.65% |
| Week 7 | $0.4897 | $0.7429 | $1.13 | -3.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc.
was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. (BIAF) is a healthcare company with a current price of $0.7666 and a market cap of $4.82M. It is ranked 5284. The price outlook is mixed, with a year-by-year forecast ranging from near the current price in 2026 to higher targets in later years, including a peak in the 2040s and 2050.
The forecast for 2026 shows an average price of $0.7666 with 0% ROI, and the sequence includes declines in several years before upside potential appears later.
A major floor 96.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 145.2% above — a clean break opens room to run.
A major ceiling 518.3% above — clearing it would confirm fresh momentum.
Key BIAF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIAF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7944 | Sell | $0.7905 | Sell |
| MA 10 | $0.8092 | Sell | $0.829 | Sell |
| MA 20 | $0.9265 | Sell | $0.9732 | Sell |
| MA 50 | $1.48 | Sell | $1.40 | Sell |
| MA 100 | $1.95 | Sell | $1.81 | Sell |
| MA 200 | $1.91 | Sell | $3.84 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.83 | Buy |
| Stoch RSI (14) | 54.25 | Neutral |
| CCI (20) | -61.86 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -9.02 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.62 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 34.61 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.78 | Sell |
| ADX (14) | 39.68 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL. RSI(14) is 30, and the stock trades around the short-term moving averages SMA50 ($1.48) and SMA200 ($1.91). The near-term support sits at $0.767 and resistance at $1.88, with the 30-day range spanning from $0.5178 to $1.13. The stock also shows high volatility, with annualized volatility at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.75 | $0.7666 | $0.9377 | 0% | Neutral | |
| $0.5131 | $0.7072 | $1.05 | -8% | Neutral | |
| $0.4316 | $0.6322 | $1.00 | -18% | Bearish | |
| $0.3357 | $0.5179 | $0.8634 | -32% | Bearish | |
| $0.4145 | $0.6704 | $1.16 | -13% | Neutral | |
| $0.4913 | $0.8305 | $1.49 | +8% | Neutral | |
| $0.5119 | $0.9027 | $1.67 | +18% | Neutral | |
| $0.5077 | $0.9323 | $1.78 | +22% | Bullish | |
| $0.3905 | $0.746 | $1.46 | -3% | Neutral | |
| $0.395 | $0.7843 | $1.57 | +2% | Neutral | |
| $0.5043 | $1.12 | $2.46 | +46% | Bullish | |
| $0.6756 | $1.50 | $3.45 | +96% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.75 | $0.7666 | $0.8892 | +0.00% |
| August 2026 | $0.5821 | $0.705 | $0.8893 | -8.04% |
| September 2026 | $0.5886 | $0.7231 | $0.9313 | +2.57% |
| October 2026 | $0.5579 | $0.6938 | $0.9092 | -4.05% |
| November 2026 | $0.5234 | $0.6576 | $0.8743 | -5.22% |
| December 2026 | $0.5486 | $0.6961 | $0.9377 | +5.85% |
Click any year to see its month-by-month BIAF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
bioAffinity Technologies, Inc.'s 2026 outlook centres on $0.7666, within a $0.75 to $0.9377 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BIAF could reach as high as $1.05, with a base case around $0.7072 and support toward $0.5131 — roughly -8% from $0.7666. Price action looks broadly range-bound.
Expect BIAF to range from $0.4316 to $1.00 through 2028. The $0.6322 average target implies a -18% move from current prices. That is -11% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The BIAF price prediction for 2029 points to an average of $0.5179 (low $0.3357, high $0.8634) — a potential decline of -32% on today's $0.7666. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, BIAF is projected to trade between $0.4145 and $1.16, averaging $0.6704 — a potential decline of -13% from today's $0.7666. That is up +29% on the projected 2029 average. A consolidation phase looks the most probable path here.
bioAffinity Technologies, Inc.'s 2031 outlook centres on $0.8305, within a $0.4913 to $1.49 range. That is up +24% on the projected 2030 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2032, BIAF could reach as high as $1.67, with a base case around $0.9027 and support toward $0.5119 — roughly +18% from $0.7666. A consolidation phase looks the most probable path here.
Expect BIAF to range from $0.5077 to $1.78 through 2033. The $0.9323 average target implies a +22% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The BIAF price prediction for 2034 points to an average of $0.746 (low $0.3905, high $1.46) — a potential decline of -3% on today's $0.7666. A consolidation phase looks the most probable path here.
In 2035, BIAF is projected to trade between $0.395 and $1.57, averaging $0.7843 — a potential gain of +2% from today's $0.7666. That is up +5% on the projected 2034 average. Price action looks broadly range-bound.
bioAffinity Technologies, Inc.'s 2040 outlook centres on $1.12, within a $0.5043 to $2.46 range. That is up +43% on the projected 2035 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BIAF could reach as high as $3.45, with a base case around $1.50 and support toward $0.6756 — roughly +96% from $0.7666. Momentum favours further upside here.
Investing $1,000 in BIAF today (≈ 1,304.461258 BIAF) could be worth
$1,958.49
+$958.49 (+96%) by 2050 · US Dollar
Based on the average projected BIAF price of $1.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIAFwould be worth at today's price.
$1,000 invested in BIAF on Jul 10, 2025 (≈ 107.52688 BIAF) would be worth
$82.43
-$917.57 (-91.8%) today · 0.08× · US Dollar
Based on a BIAF entry price of $9.3 vs. today's $0.7666.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.83 | $923.61 | -7.6% |
| 1 month ago | $1.52 | $504.34 | -49.6% |
| 3 months ago | $3.35 | $228.84 | -77.1% |
| 6 months ago | $1.27 | $603.62 | -39.6% |
| 1 year ago | $9.3 | $82.43 | -91.8% |
| All time (3.9y) ago | $249 | $3.08 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIAF forecast.
Our base-case forecast reaches $1.50 around 2050.
Implied market cap at $1.50: $9.42M
The multi-year forecast shows a mixed trajectory. In 2030 the average price is $0.6699 with a -12.6% ROI and NEUTRAL sentiment. By 2040 the average rises to $1.12 with a 46% ROI and a BULLISH sentiment.
In 2050 the average is $1.51 with a 96.8% ROI and a BULLISH sentiment. Earlier years feature declines, such as 2027 with an average of $0.7061 and -7.9% ROI and 2029 with an average of $0.5192 and -32.3% ROI. The forecast also shows a max of $1.16 in 2030, $2.46 in 2040, and a max of $3.47 in 2050.
These figures are estimates, not guarantees, and reflect periods of volatility with potential upside in later years as indicated by the 2040 and 2050 outlooks.
Tap a question to reveal the answer.
Avg price $0.6699, min $0.4141, max $1.16, ROI -12.6%, sentiment NEUTRAL.
Forecasts show a mix of outcomes: 2026 avg $0.7666 (ROI 0%), declines in 2027-2029, then higher targets in 2040 and 2050 with avg prices of $1.12 (ROI 46%) and $1.51 (ROI 96.8%), with sentiment moving from NEUTRAL/Bearish to Bullish over time.
Yes. The forecast includes higher max prices in multiple years, including max $1.16 in 2030, max $1.77 in 2033, max $2.46 in 2040, and max $3.47 in 2050.
Current price $0.7666, market cap $4.82M, rank 5284.
Sentiment NEUTRAL; RSI(14) 30; SMA50 $1.48; SMA200 $1.91; support $0.767; resistance $1.88; 30-day range $0.5178 to $1.13; annualized volatility 100%.
bioAffinity Technologies, Inc. Community Discussion
0Share your bioAffinity Technologies, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.